Venous Return Pressure Gradient as a Predictor of Acute Kidney Injury (NCT07722325) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Venous Return Pressure Gradient as a Predictor of Acute Kidney Injury
180 participantsStarted 2026-07-05
Plain-language summary
Acute kidney injury (AKI) is a common and serious complication in the ICU. Current diagnostic indicators (such as creatinine and urine output) exhibit significant lag, and specific hemodynamic predictive markers are lacking. The venous return pressure gradient (Pmsf-CVP), based on Guyton's theory, reflects the driving pressure for venous return; however, its value in the early warning of AKI remains unclear. This study aims to investigate the predictive value of the venous return pressure gradient for the onset and progression of AKI in ICU patients, and to clarify its effectiveness as an AKI risk warning indicator.
Patients admitted to the ICU within 48 hours with risk factors for AKI (including sepsis, shock, major surgery, underlying diseases, etc.) who have radial artery catheterization and can undergo hemodynamic monitoring will be enrolled. Those undergoing maintenance dialysis/CRRT, ECMO support, or with missing core data precluding calculation of Pmsf-CVP or AKI assessment will be excluded.
The venous return pressure gradient (Pmsf-CVP, mmHg) will be measured within 48 hours of ICU admission using the transient stop-flow arm arterial-venous equilibrium pressure method. The primary outcome is to evaluate the association between the venous return pressure gradient level and AKI occurrence. Secondary outcomes include correlation analyses between the venous return pressure gradient level and serum creatinine and urine output within 48 hours of ICU admission, among others.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years
. Admitted to the intensive care unit (ICU) within 48 hours
. Central venous catheter in place for continuous central venous pressure (CVP) monitoring
. Radial artery catheter in place for hemodynamic monitoring including mean systemic filling pressure (Pmsf)
. No acute kidney injury (AKI) at ICU admission according to KDIGO criteria
Exclusion criteria
. Maintenance hemodialysis or continuous renal replacement therapy (CRRT) prior to ICU admission
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is described as 'not yet recruiting' — do you know when it's expected to open, and would it even make sense for me to wait for it given my current situation with AKI risk?
2The study is measuring something called the 'venous return pressure gradient' as a predictor of acute kidney injury — can you explain what that measurement involves for me physically, and whether it would change anything about my care or just contribute to research data?
3Since this trial appears to be observational rather than a treatment study, does participating mean I'd still receive the same standard treatment I would otherwise get, with no changes to my actual care?
4This study is listed as Phase NA, which often means it's not testing a new drug or device but rather collecting data — how would my participation actually benefit my own treatment decisions, if at all, versus primarily helping future patients?
5Are there other ways my kidney function is already being monitored that overlap with what this trial tracks, and would joining this study create any additional burden or procedures beyond what I'd normally go through?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.